Tag: Drug

Class action lawsuit filed against Amylyx Pharmaceuticals for securities violations, alleging overstated drug prospects and failure to disclose key information. ...

Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...

Artificial Intelligence (AI) is revolutionizing industries without posing a threat to job security. It enhances work processes, stimulates job creation, ...

Vertex Pharmaceuticals is capturing the attention of investors with its expansion into pain management and cell/gene therapies. With positive earnings ...

AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...

Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...

NRx Pharmaceuticals receives a $5 million milestone payment for the development of its drug candidate NRX-101, supporting its progress through ...

Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...

Cidara Therapeutics receives $11.1 million milestone payment from Mundipharma for European approval of new antifungal drug, Rezzayo. Analysts see potential ...

Tango Therapeutics receives positive coverage from Piper Sandler, emphasizing its strong position in precision oncology. The firm believes the company's ...